Sutro Biopharma showcases next-gen ADC pipeline strength at AACR 2026
Sutro Biopharma (NASDAQ:STRO) unveiled a series of preclinical successes at the 2026 American Association for Cancer Research (AACR) Annual Meeting, reinforcing its leadership in the design of next-generation antibody-drug conjugates (ADCs).










